Immunotherapy with Chimeric Antigen Receptor (CAR) T Cells, T cells whose receptor has been genetically modified, is based on improving the immune response against the tumor. This approach is promising for patients with hematologic malignancies refractory to chemotherapy. Despite impressive results, too many patients are relapsing. The reasons for the relapse, after the injection of CAR T cells, need to be explored. In this context of newly introduced therapeutics, it is essential to better understand the factors associated with the response to treatment with CAR T Cells, especially the characteristics of the tumor and its microenvironment.

The objective of this study is to understand the role of tumor biology, and its microenvironment, in the response to CAR-T Cells therapy in patients with hematologic malignancies

Inclusion Criteria:

• patient with hematological malignancy (lymphoma, ALL, MM)
• patient integrated into a CAR-T Cells program treatment
• patient aged 15 years or over
• patient having signed a written consent; as well as his legal representative if <18 years old

Exclusion Criteria:

• patient with other hematological malignancies than lymphoma, LAL or MM
• patient's weight <58 kg
• patient treated with another treatment than CAR-T Cells
• patient under tutorship or curatorship
• patient not covered by a health system

Patients with hematological malignancy